Bugs & Drugs

I found that I was losing the plot about what was where! Here’s my quick guide to priority pathogens and pipeline reviews. Corrections and amends gratefully received.

Priority Pathogen / Threat Lists

  • CDC 2019: Newsletter is here, report itself is here.
  • WHO 2017: Newsletter is here, report itself is here.
  • CDC 2013: Report itself is here.
  • ESKAPE list 2008-9: The original papers are here:
    • (link) Rice LB. Federal funding for the study of antimicrobial resistance in nosocomial pathogens: no ESKAPE. J Infect Dis. 2008;197(8):1079-81.
    • (link) Boucher HW et al. Bad Bugs, No Drugs: No ESKAPE! An Update from the Infectious Diseases Society of America. Clinical Infectious Diseases. 2009;48(1):1-12
  • Comparative summary of all 4 priority pathogen lists as a PowerPoint deck is here.
    • Please also see this newsletter for a further discussion of the priority pathogen lists as well as the idea of first- vs. best-in-class. 

Pipeline Reviews

  • Reviews by WHO
    • WHO 2019: My newsletter is here, commentary by WHO staff is here, the pre-clinical pipeline review is here and is supported by a data-mining interface here; the clinical pipeline review is here.
    • WHO 2017: Newsletter is here, report is here, and manuscript about the review is here.
  • Reviews by the Pew Trusts (all updated as of April 2020)
    • Go here for traditional therapeutics.
    • Go here for a visualization of pipeline changes during 2014-2019.
    • Non-traditional products are separately summarized here.
  • Independent reviews

Nature publishes superb 10-paper collection on all things AMR

Dear All,  Released on 21 Oct 2020, Nature has published has published an Outlook series on AMR. The papers are 2-4 pages long and provide an excellent survey of all things AMR. See below the list of papers with brief comments on content. All the papers are good; special highlights for me were #2 (economics)

NIAID Small Business Application Assistance Program seeks applications!

Dear All, National Institute of Allergy and Infectious Diseases (NIAID) put out a call on 22 Oct 2020 for applications for its Applicant Assistance Program (AAP). The AAP provides no cost support for US-based companies planning to apply for a Phase II, Fast Track, or Direct-to-Phase II Small Business Innovation Research (SBIR) or Small Business Technology

Scroll to Top